About Us
Flatbird Therapeutics
Founded in 2023, is a next-generation biopharma company committed to reshaping women's health across the full lifecycle. Headquartered in New York with an innovation center in Nanjing and commercialization hub in Suzhou, we combine modernized herbal medicine with small-molecule immunomodulatory technologies to develop safe, evidence-based interventions in areas such as anti-HPV research, HPV-related cancer prevention, female reproductive immunology, and mucosal microenvironment regulation.
The company operates under an integrated R&D-to-market model, with three major pipelines under active development. Flagship products include CERLIMA®, a globally innovative topical gel targeting HPV via immune modulation, and Quannuoning®, a broad-spectrum botanical antiviral formulation. Our founding team consists of global pharma executives, clinical gynecology experts, and translational scientists, united by a shared mission to deliver safe, hormone-free, and science-driven health solutions for women worldwide.
Scientific Empowerment
Empower women with clinically proven, hormone-free, and science-based solutions for HPV, intimate wellness, and long-term reproductive health.
Global Innovation for Women’s Health
Build a global innovation engine that bridges herbal science and modern medicine to reshape women’s health across the full lifecycle.
Accessibility & Affordability
Deliver affordable and accessible medical-grade products to underserved populations, ensuring equitable care across geographies and income levels.
From Infection to Prevention
Transform the disease management paradigm by moving from reactive treatment to proactive prevention and early intervention.